Philips launches IntraSight Plus to simplify coronary interventions and advance precision care

March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care With FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510(k) clearance, the redesigned platform combines the most comprehensive diagnostic and treatment planning tools to deliver efficiency, simplicity and precision in a single intuitive system [1].